Trial Profile
Immune response and safety of AE 37 plus HER2/Neu GP2 vaccine in patients with breast and ovarian cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Aug 2014
Price :
$35
*
At a glance
- Drugs AE 37 (Primary) ; HER2/Neu GP2 vaccine Greenwich LifeSciences Inc/NuGenerex Immuno-Oncology (Primary)
- Indications Breast cancer; Ovarian cancer
- Focus Adverse reactions; Pharmacodynamics
- 08 Aug 2014 New trial record